Record-Breaking Quarterly Revenue
The company recorded revenue of $5.1 million in the fourth quarter of 2024, an increase of 5% compared to $4.8 million in the same period in 2023.
Improved Gross Margin
Gross margin increased to approximately 53% in Q4 2024, compared to 49% in Q4 2023, due to supply chain improvements and reduced service costs.
Decreased Operating Expenses
Operating expenses for Q4 2024 were $4.9 million, a 15% decrease compared to $5.8 million for Q4 2023, primarily due to a decrease in headcount and discretionary payroll.
Positive Gross Margin Trend
For the full year 2024, gross profit was $9.5 million, with a gross margin of 53%, compared to a gross margin of 50% in 2023.
Successful CMS Pricing Determination
CMS established pricing determination for the Ekso Indigo Personal device in Q2 2024, creating a significant opportunity to help Medicare enrollees living with spinal cord injuries.
Engagement with Priya Healthcare
Engaged Priya Healthcare to help navigate the complexities of CMS reimbursement, enhancing the ability to submit Medicare claims.
Exclusive Distribution with National Seating and Mobility
Ekso Bionics partnered with National Seating and Mobility as the exclusive distributor within the CRT industry in the United States, expanding access to Ekso Indigo Personal.